Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
(By Rachel Cohrs and J. Emory Parker for STAT) The Food and Drug Administration’s decision to grant wide-ranging approval to
Read More(By Rachel Cohrs and J. Emory Parker for STAT) The Food and Drug Administration’s decision to grant wide-ranging approval to
Read More(By Drew Altman for Kaiser Family Foundation, published June 25, 2021) The fact that prescription drugs represent just 10% of national
Read More(By Phil Galewitz for NPR) When doctors at a primary care clinic in Philadelphia noticed many of its poorest patients
Read More(By Katie Adams for Becker’s Hospital Review) Biogen’s Alzeheimer’s drug Aduhelm could single-handedly represent 1 percent of all national healthcare
Read MoreAccording to a recent Edward Jones and Age Wave study, healthcare costs is the top money-related concerns for individuals retiring. The
Read More(By Katie Adams for Becker’s Hospital Review) As more drugs enter the market with five-figure annual list prices, a large
Read More(By Jay Hancock for Kaiser Health News) After falling from a ladder and cutting his arm, Ed Knight said, he
Read More(By Morgan Haefner for Becker’s Hospital Review) UnitedHealthcare is delaying a policy that could have led to retroactive denials for emergency
Read More(By Rachel Bluth for Kaiser Health News) It took covid-19 to give millions of Americans the option of telling their
Read More(By Bernard J. Wolfson for Kaiser Health News) In April, San Francisco-based primary care company One Medical revealed an eye-popping
Read More